An Open-label, Roll-over Safety Study of AGI-003 (Arverapamil) in the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)

Trial Profile

An Open-label, Roll-over Safety Study of AGI-003 (Arverapamil) in the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs R-verapamil (Primary)
  • Indications Irritable bowel syndrome
  • Focus Adverse reactions; Registrational
  • Acronyms ARDIS-3
  • Sponsors AGI Therapeutics
  • Most Recent Events

    • 22 Sep 2009 AGI Therapeutics announced in a media release that it has completed the data analysis of ARDIS-1 and-3.
    • 22 Sep 2009 Status changed from recruiting to completed. This trial enrolled 349 patients and is completed according to an AGI Therapeutics media release.
    • 09 Sep 2008 Status changed from planning to recruiting. Currently 80% of patients completing ARDIS-1 are rolling over into ARDIS-3.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top